Legal & General Group Plc lifted its holdings in shares of TESARO Inc (NASDAQ:TSRO) by 2.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,297 shares of the biopharmaceutical company’s stock after buying an additional 1,079 shares during the quarter. Legal & General Group Plc owned about 0.07% of TESARO worth $4,944,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Hanseatic Management Services Inc. lifted its stake in TESARO by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 5,936 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 15 shares in the last quarter. Stephens Inc. AR lifted its stake in TESARO by 6.5% in the 2nd quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 115 shares in the last quarter. Cornerstone Capital Management Holdings LLC. lifted its stake in TESARO by 1.1% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 12,092 shares of the biopharmaceutical company’s stock worth $1,690,000 after purchasing an additional 136 shares in the last quarter. Aperio Group LLC lifted its stake in TESARO by 4.5% in the 2nd quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 156 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in TESARO by 15.4% in the 2nd quarter. Advisors Asset Management Inc. now owns 4,076 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 543 shares in the last quarter.

TESARO Inc (TSRO) opened at $77.85 on Tuesday. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. TESARO Inc has a twelve month low of $77.20 and a twelve month high of $192.94.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. During the same quarter last year, the firm earned ($1.72) EPS. The firm’s quarterly revenue was up 740.3% compared to the same quarter last year. sell-side analysts expect that TESARO Inc will post -8.17 EPS for the current year.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now directly owns 6,943 shares in the company, valued at approximately $823,439.80. The disclosure for this sale can be found here. 34.60% of the stock is currently owned by company insiders.

Several research firms have issued reports on TSRO. Robert W. Baird reiterated a “hold” rating and issued a $120.00 target price on shares of TESARO in a research note on Friday, November 10th. Wedbush reiterated an “outperform” rating and issued a $160.00 target price on shares of TESARO in a research note on Monday, September 11th. Leerink Swann upgraded shares of TESARO from a “market perform” rating to an “outperform” rating in a research note on Wednesday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $158.00 target price on shares of TESARO in a research note on Monday, November 20th. Finally, Barclays began coverage on shares of TESARO in a research note on Monday, October 23rd. They issued an “equal weight” rating and a $135.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $159.39.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/legal-general-group-plc-acquires-1079-shares-of-tesaro-inc-tsro/1772669.html.

TESARO Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.